MYUNGMOON PHARM CO.,LTD Logo

MYUNGMOON PHARM CO.,LTD

Develops, manufactures, and commercializes prescription & OTC medicines for global markets.

017180 | KO

Overview

Corporate Details

ISIN(s):
KR7017180001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 26, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Myungmoon Pharm. Co., Ltd., established in 1983, is a research-based pharmaceutical company engaged in the development, manufacturing, and commercialization of healthcare products. The company's portfolio includes a range of ethical (ETC) prescription drugs and over-the-counter (OTC) medicines. It operates through the entire pharmaceutical value chain, from research and development to the import, export, and distribution of its products. Myungmoon Pharm serves both the domestic South Korean market and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.7 KB
2025-03-26 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 206.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 222.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 203.2 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.1 KB
2025-01-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 21.4 KB
2025-01-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 25.7 KB
2024-11-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB

Automate Your Workflow. Get a real-time feed of all MYUNGMOON PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MYUNGMOON PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MYUNGMOON PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.